Portal de Periódicos da CAPES

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study

2019; Lippincott Williams & Wilkins; Volume: 38; Issue: 1 Linguagem: Inglês

10.1200/jco.19.01056

1527-7755

Michael S. Khodadoust, Alain H. Rook, Pierluigi Porcu, Francine Foss, Alison J. Moskowitz, Andrei R. Shustov, Satish Shanbhag, Lubomir Sokol, Steven P. Fling, Nirasha Ramchurren, Robert H. Pierce, Asa K. Davis, Richard Shine, Shufeng Li, Sophia Yui Kau Fong, Jinah Kim, Yi Yang, Wendy M. Blumenschein, Jennifer H. Yearley, Biswajit Das, Rajesh Patidar, Vivekananda Datta, Erin Cantu, Justine N. McCutcheon, Chris Karlovich, P. Mickey Williams, Priyanka B. Subrahmanyam, Holden T. Maecker, Sarah McCue Horwitz, Elad Sharon, Holbrook E. Kohrt, Martin A. Cheever, Youn H. Kim,

CAR-T cell therapy research

To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).